

Hansa Medical

- PRESS RELEASE -

September 6, 2018

Issue and repurchase of class C shares for incentive program

By virtue of authorization by the annual general meeting held on 29 May 2018, the board of directors of Hansa Medical AB (publ) has resolved to issue and immediately thereafter repurchase 391,503 class C shares. The shares are issued and repurchased in accordance with the incentive programme LTIP 2018, which was adopted by the annual general meeting held on 29 May 2018.

Carnegie Investment Bank AB will subscribe for the entire issue of new class C shares at a subscription price of SEK 1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors' resolution, be repurchased by Hansa Medical for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2018.

The purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right. Hansa Medical has previously issued 330,261 class C shares.

The information was submitted for publication, through the agency of the contact person set out below, at 16:30am CEST on September 6, 2018.

For further information, please contact:

Hansa Medical AB (Publ)

Emanuel Björne, Vice President Business Development and Investor Relations

Mobile: +46707175477

E-mail: emanuel.bjorne@hansamedical.com

www.hansamedical.com

About Hansa Medical

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, imlifidase (IdeS), is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin-cleaving enzymes are developed for repeat dosing with the objective of applying the Hansa Medical technology in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on Nasdaq Stockholm (ticker: HMED).